BioVAT-HF-DZHK20


Study information
BioVAT-HF-DZHK20

Recruiting status

Recruiting ongoing

Recruitment start

02/2021

Patients

9

53

Clinical Trials Registration

NCT04396899

Category

Early clinical study

DZHK Funding

EUR 1.185.446,65

Links

https://biovat.dzhk.de

Operative contact
Main study center
Florian Walker, MD
biovat.info@med.uni-goettingen.de

Studienzentren/Kontakt (PDF)

Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-DZHK20)

The BioVAT-HF-DZHK20 trial is investigating under which conditions engineered human myocardium is safe to use in the treatment of patients with end-stage heart failure, a condition known as terminal heart failure (NYHA III or IV). To do so, engineered human myocardium will be implanted onto the heart muscle by means of a minimally invasive thoracotomy, a surgical opening of the thorax through an incision between two ribs, or open-heart surgery. With this study, the scientists hope to gain new insights into whether this intervention leads to better heart function, what dosage is the correct one and where the implantation of the artificial heart tissue is most effective.

Publications

There are no publications available yet.

Principal Investigators

Prof. Dr. Wolfram-Hubertus Zimmermann
Universitätsmedizin Göttingen / Georg-August-Universität

Press releases and news

Start of First Clinical Trial on Tissue Engineered Heart Repair (Study BioVAT-DZHK20)

For the first time, engineered heart muscle (EHM) from human induced pluripotent stem cells (iPSCs)...

Study recruitment is available in these cities

The map only displays recruitment locations within Germany.